Derivation Web

source_b2e5eec4facb466d

by researka:v2 · 2026-07-26 13:22:05.193176+04:00

# Research Synthesis: Metformin Intervention Metformin Treatment Effects — full paper

## Abstract

Evidence scope: 18/33 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Metformin occupies an unusual translational position: a decades-old glucose-lowering agent with a safety profile that has prompted systematic exploration of cardiometabolic, immune, frailty, and longevity endpoints beyond diabetes (Anisimov 2008), yet evidence remains fragmented across dozens of small, heterogeneous trials.

The present report is an AI-assisted structured evidence synthesis built on 33 curated references, each linked to a source describing study design, population, outcome class, and directness, with an explicit audit trail flagged for cross-domain and directness tensions.

Across the corpus, the synthesis supports a position that metformin produces consistent, modest HbA1c benefit when used as combination therapy in type 2 diabetes, but the broader aging case—inflammation modification, frailty prevention, longevity extension, and weight-independent cardiometabolic protection—remains hypothesis-generating rather than demonstrated, with cross-domain and direct-versus-indirect tensions explicitly unresolved.

Uncertainty persists because the strongest direct RCTs are short-term and disease-specific, while indirect observational signals on aging endpoints have not been replicated in adequately powered, long-duration randomized trials of non-diabetic older adults.

## Research Question

Within the retained source corpus for metformin intervention metformin treatment effects, among adults, do findings for cardiometabolic and contextual adjacent evidence support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on metformin intervention metformin treatment effects across 33 included source papers and 2183 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 15 direct clinical sources, 18 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for metformin intervention metformin treatment effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Schiapaccassa 2019 [bundle:33], Park 2024 [bundle:2], Qin 2025 [bundle:3] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the contextual adjacent evidence, frailty and cardiometabolic outcome classes; and negative or adverse signals around the cardiometabolic, immune and inflammation outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_intervention_metformin_treatment_effects-v06-DAILY-2026-07-26T09-04-54Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-26.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `metformin intervention metformin treatment effects aging`
- `metformin intervention metformin treatment effects older adults`
- `metformin intervention metformin treatment effects randomized controlled trial`
- `metformin aging`
- `metformin older adults`
- `metformin randomized controlled trial`
- `intervention metformin treatment aging`
- `intervention metformin treatment older adults`
- `intervention metformin treatment randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses metformin intervention metformin treatment effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 151 records in the receipt-candidate union, 32 were classified as source candidates and 33 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 151 |
| Classified source candidates | 32 |
| No extractable claims | 30 |
| None-only claim binding | 5 |
| Mixed partial-or-none claim-binding candidates | 42 |
| Partial-only claim-binding candidates | 31 |
| Strict high-confidence sources | 11 |
| Admitted final sources | 33 |

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune and inflammation, longevity, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 33 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. source-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting.

Direction heterogeneity note: Cardiometabolic: mixed=1 (Shen 2026 [bundle:23]); negative=3 (Mohan 2026 [bundle:5], Kumari 2026 [bundle:15], Agarwal 2026 [bundle:16]); null=1 (Comparison of Efficacy and Safety 2022 [bundle:32]); positive=3 (Malin 2026a [bundle:6], Han 2020 [bundle:7], Hu 2021 [bundle:9]); unclear=11 (Guo 2026 [bundle:1], Park 2024 [bundle:2], Qin 2025 [bundle:3]). Immune and Inflammation: mixed=1 (Schiapaccassa 2019 [bundle:33]); negative=1 (Effects of Metformin on Biomarkers 2026 [bundle:31]).

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Agarwal 2026: Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=51 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Behbudi 2025: Effect of Metformin on Clinical Course of Non-Diabetic Patients with Ischemic Stroke | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.021; source-level statistic reported |
| Cardiometabolic | Comparison of Efficacy and Safety 2022: Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=representative statistic P < 0.05; source-level statistic reported |
| Cardiometabolic | Espinoza 2025a: A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=11 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Guo 2021: Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Guo 2026: HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=170 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Han 2020: Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.002; source-level statistic reported |
| Cardiometabolic | Hu 2021: Effects of a Behavioral Weight Loss Intervention and Metformin Treatment on Serum Urate: Results from a Randomized Clinical Trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=73 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Inzucchi 2020: MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Kim 2024: A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study) | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=70 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Kumari 2026: Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus | direction=negative | directness=indirect | B2 | outcome=Cardiometabolic; direction=negative | finding=representative statistic P = 0.022; source-level statistic reported |
| Cardiometabolic | Malin 2026a: Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.017; source-level statistic reported |
| Cardiometabolic | Malin 2026b: Metformin Alters Exercise Training Induced Blood Pressure and Aortic Waveform Adaptations in Adults at Risk for Metabolic Syndrome | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.051; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Mohan 2026: Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=132 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Park 2024: Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=161 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Qin 2025: Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=149 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Sahay 2026: Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=144 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Shadyab 2025: Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=34 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Shen 2026: Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Bilusic 2026: The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=17 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Espinoza 2025b: METFORMIN TO TARGET FRAILTY IN OLDER ADULTS | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=11 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Iraji 2026: Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in the Treatment of Melasma | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=65 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Li 2025: Medication count, including statin or metformin use, is not associated with influenza vaccine responses in older adults | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=49 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Marcelo-Calvo 2026: Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=65 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Mueller 2021: Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=107 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | R 2026: Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=20 extracted claim(s); source-level direction is the coded finding |
| Frailty | Espinoza 2022: CLINICAL TRIAL OF METFORMIN FOR FRAILTY PREVENTION IN COMMUNITY-DWELLING OLDER ADULTS WITH PRE-DIABETES | direction=null | directness=indirect | B2 | outcome=Frailty; direction=null | finding=13 extracted claim(s); source-level direction is the coded finding |
| Frailty | Tavabi 2021: A Randomized Placebo-Controlled Trial of Metformin for Frailty Prevention in Older Adults | direction=null | directness=direct | A1 | outcome=Frailty; direction=null | finding=15 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Effects of Metformin on Biomarkers 2026: 3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial | direction=negative | directness=direct | A1 | outcome=Immune and Inflammation; direction=negative | finding=2 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Schiapaccassa 2019: 30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study | direction=mixed | directness=direct | A1 | outcome=Immune and Inflammation; direction=mixed | finding=229 extracted claim(s); source-level direction is the coded finding |
| Longevity | Maio 2026: Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=41 extracted claim(s); source-level direction is the coded finding |
| Longevity | Orchard 2021: Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults. | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=8 extracted claim(s); source-level direction is the coded finding |
| Safety and Comorbidity | Abed 2024: Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee osteoarthritis: randomized clinical trial | direction=unclear | directness=direct | A1 | outcome=Safety and Comorbidity; direction=unclear | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Metformin Intervention Metformin Treatment Effects / Cardiometabolic | n=19; claims=1495 | significant source statistic in 17/19 sources; receipt-level direction coded unclear | 9 direct; 10 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Contextual Adjacent Evidence | n=7; claims=334 | significant source statistic in 5/7 sources; receipt-level direction coded unclear | 2 direct; 5 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Frailty | n=2; claims=28 | no extracted directional signal in 2/2 sources | 1 direct; 1 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Immune and Inflammation | n=2; claims=231 | negative signal in 1/2 sources | 2 direct | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Longevity | n=2; claims=49 | unclear signal in 2/2 sources | 2 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Safety and Comorbidity | n=1; claims=46 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 direct | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 7 sources; significant source statistic in 4/7 sources; receipt-level direction coded unclear.
- Oncology and cancer context: 3 sources; significant source statistic in 1/3 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 2 sources; significant source statistic in 1/2 sources; receipt-level direction coded unclear.
- Infectious-disease and immunology context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

### Results Summary

- Cardiometabolic: n=19; claims=1495; mixed signal in 11/19 sources | directness: 9 direct; 10 indirect; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=7; claims=334; mixed signal in 5/7 sources | directness: 2 direct; 5 indirect; main limitation: directionally heterogeneous.
- Frailty: n=2; claims=28; no extracted directional signal in 2/2 sources | directness: 1 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Immune and Inflammation: n=2; claims=231; mixed signal in 1/2 sources | directness: 2 direct; main limitation: directionally heterogeneous.
- Longevity: n=2; claims=49; mixed signal in 2/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=1; claims=46; mixed signal in 1/1 sources | directness: 1 direct; main limitation: single-source support.

### Cardiometabolic Outcomes

The cardiometabolic outcome class constitutes the dominant evidentiary spine of this synthesis, drawing on 19 distinct sources spanning clinical RCTs, mechanistic human studies, and observational cohorts. Across this corpus, metformin's role is consistently examined as background therapy against which adjuncts are layered, rather than as a monotherapy in isolation. Together these two trials establish that the metformin background platform supports multiple adjunct strategies with detectible, dose- or arm-dependent HbA1c effects, and the evidence synthesis carries every study × p-value tuple so individual contrasts are not duplicated here.

A second cluster of direct clinical RCTs compares metformin against active comparators or examines metformin as a foundation under newer agents. Qin 2025 [bundle:3] conducted a single-center, prospective, randomized, controlled, noninferiority study of sitagliptin versus gliclazide combined with metformin in treatment-naive patients with type 2 diabetes, incorporating genetic polymorphism analysis; efficacy contrasts yielded a mixture of significant differences (P < 0.05, P = 0.012, P < 0.001, P = 0.027, P = 0.010, P = 0.023) and null contrasts (P > 0.05, P = 0.193, P = 0.937, P = 0.522, P = 0.073, P = 0.053, P = 0.081, P = 0.464, P = 0.605, P = 0.692, P = 0.653, P = 0.753). Comparison of Efficacy and Safety 2022 [bundle:32] randomized Indian patients with type 2 diabetes on background metformin to vildagliptin 50 mg twice daily versus vildagliptin 100 mg sustained-release once daily and reported HbA1c reductions (P < 0.05).

Beyond HbA1c, mechanistic human RCTs probe cardiometabolic substrates including liver fat, urate, body composition, blood pressure, and frailty endpoints. Agarwal 2026 [bundle:16] randomized overweight and obese women with polycystic ovary syndrome, diagnosed by Rotterdam criteria, to dapagliflozin plus metformin versus metformin alone in an open-label, parallel, randomized controlled trial; key contrasts reached significance (P < 0.001, P < 0.05). Mechanistically, these trials suggest that metformin and metformin-based regimens engage glycemic, hepatic, urate, and body-composition pathways, but the magnitude and direction of any single substrate's response depends on the comparator arm and population.

Indirect observational evidence complements the RCT layer by extending metformin cardiometabolic effects to non-diabetic and longevity contexts. Malin 2026a [bundle:6], a double-blind, placebo-controlled trial in adults at risk for metabolic syndrome randomized to low-intensity exercise plus placebo versus metformin co-administration, reported multiple metabolic-insulin-sensitivity contrasts (P = 0.017, P = 0.008, P = 0.025, P = 0.002, P = 0.01, P < 0.001, P = 0.048, P = 0.094, P = 0.093, P = 0.119, P = 0.104, P = 0.045, P = 0.041, P = 0.477, P = 0.061, P = 0.004, P = 0.02, P = 0.055, P = 0.747, P = 0.096, P = 0.756, P = 0.068, P = 0.009, P = 0.208, P = 0.529, P = 0.640, P = 0.367). Within-corpus tensions in this outcome class are most visible on the body-mass-index, body-weight, and HbA1c axes, where direct RCTs and indirect observational cohorts disagree. On BMI, Hu 2021 [bundle:9] reports a positive signal whereas Kim 2024 [bundle:10], Agarwal 2026 [bundle:16], Mohan 2026 [bundle:5], and Sahay 2026 [bundle:4] yield null contrasts, framing a partial conflict between behavioral-plus-metformin combination therapy and metformin-as-background add-on or comparator designs. On body weight, Malin 2026a [bundle:6] is positive whereas Malin 2026b [bundle:11] is null, reflecting different endpoint domains within the same parent trial; Kumari 2026 [bundle:15] is negative for body-mass-index whereas Guo 2026 [bundle:1] and Guo 2021 [bundle:14] are null. On HbA1c, Mohan 2026 [bundle:5] is negative for triple-combination effect magnitude whereas Sahay 2026 [bundle:4] and Han 2020 [bundle:7] produce null contrasts for their respective primary comparisons. Insulin sensitivity shows Agarwal 2026 [bundle:16] as negative and Qin 2025 [bundle:3] as null. Across these contrasts, the direct versus indirect evidence layering remains a structural feature of the corpus: direct RCTs such as Comparison of Efficacy and Safety 2022 [bundle:32] and Kim 2024 [bundle:10] are kept analytically separate from indirect observational studies such as Shadyab 2025 [bundle:20], Behbudi 2025 [bundle:21], Espinoza 2025a [bundle:28], Kumari 2026 [bundle:15], Malin 2026a [bundle:6], Malin 2026b [bundle:11], Shen 2026 [bundle:23], Guo 2026 [bundle:1], Inzucchi 2020 [bundle:22], and Guo 2021 [bundle:14], because the inference each supports differs in kind. The cardiometabolic evidence base for Metformin is therefore best characterized as context-dependent: mechanistic plausibility coexists with mixed or sparse human RCT evidence, and the boundary conditions for any given substrate response remain to be established.

### Contextual Adjacent Evidence Outcomes

Seven curated studies populate the contextual other outcome class, spanning the gut microbiome, epigenetic age, vaccine immunology, dermatology, neurological repurposing, oncology metabolite biology, and frailty-targeted aging trials. Marcelo-Calvo 2026 [bundle:12] conducted a double-blind, placebo-controlled pilot trial — METFORAGING — in non-diabetic people living with HIV aged 50 years or older, virologically suppressed on stable antiretroviral therapy, and assessed epigenetic-age biomarkers across the metformin versus placebo arms, yielding a numeric array including P = 0.627, P < 0.001, P = 0.038, P = 0.355, P = 0.144, P = 0.759, P = 0.698, P = 0.401, P = 0.475, and P = 0.96 (Marcelo-Calvo 2026 [bundle:12]).

Mechanistically, the two direct human RCTs in this class — Mueller 2021 [bundle:8] and Marcelo-Calvo 2026 [bundle:12] — share a randomized, placebo-controlled, biomarker-endpoint architecture but interrogate entirely different substrates: Mueller 2021 [bundle:8] reads out the gut microbiome and short-chain fatty acid pool, while Marcelo-Calvo 2026 [bundle:12] reads out epigenetic-age clocks in the context of HIV and antiretroviral therapy, with the latter's p-value array (P = 0.627, P < 0.001, P = 0.038, P = 0.355, P = 0.144, P = 0.759, P = 0.698, P = 0.401, P = 0.475, P = 0.96) indicating that some epigenetic-age metrics shifted while others did not (Mueller 2021 [bundle:8]; Marcelo-Calvo 2026 [bundle:12]). The within-class pathway pluralism — microbiome, epigenetic clocks, melanin/photoaging biology, vaccine responses, CNS repurposing, tumor-metabolite biology, and frailty — is therefore real and should not be collapsed into a single mechanism.

### Frailty Outcomes

Two reference sources converge on frailty as a primary endpoint for metformin intervention in older adults. Tavabi 2021 [bundle:26] is a randomized, double-blind, placebo-controlled trial in non-frail, community-dwelling adults aged 65 years and older with pre-diabetes, designed to determine whether metformin prevents incident frailty; source excerpts define the eligibility window as a 2-hour oral glucose tolerance-based pre-diabetes criterion, and the trial is anchored to a clinical/functional endpoint rather than a glycemic surrogate. Both sources restrict their populations to older adults aged 65 and above and frame frailty as a longitudinal, prevention-oriented outcome rather than a treatment effect in already-frail participants.

Quantitative endpoint detail is carried by the evidence synthesis (Per-Study Endpoint Evidence); the prose here restricts itself to what is explicitly traceable. Tavabi 2021 [bundle:26] reports no numeric p-values, effect sizes, or hazard ratios in the supplied excerpt — only the trial architecture (randomization, placebo control, frailty-prevention endpoint in pre-diabetic non-frail elders) — and the source's effect direction field is null, consistent with a null or unreported finding in the curated excerpt. In both sources, the absence of reportable p-values and the null direction coding together indicate that, within the curated corpus, the frailty endpoint is currently characterized by null findings rather than by positive or negative signals.

Mechanistically, the frailty endpoint sits at the intersection of metabolic and functional biology, and the two sources operationalize that intersection through complementary substrates. Tavabi 2021 [bundle:26] anchors a clinical RCT design — randomization and placebo control in a pre-diabetes-defined cohort — so that any observed shift in frailty incidence can be attributed to the intervention rather than to underlying glycemic trajectory, and the eligibility criterion (2-hour oral glucose tolerance-defined pre-diabetes) implicates the same metabolic substrate that mechanistic human studies elsewhere in the corpus interrogate. Across both sources, the mechanistic substrate is human and clinical rather than preclinical, which constrains the inferential reach of any preclinical data brought in to interpret null frailty results.

The principal within-corpus tension on frailty is an indirectness gap between Tavabi 2021 [bundle:26] and Espinoza 2022 [bundle:27], both of which evaluate metformin for frailty prevention in the same population (community-dwelling older adults aged 65 and above with pre-diabetes) but differ in their directness classification: Tavabi 2021 [bundle:26] is coded as direct against the frailty outcome, while Espinoza 2022 [bundle:27] is coded as indirect. By contrast, Tavabi 2021 [bundle:26] carries the direct efficacy signal (or null) and should be the anchor citation when discussing whether metformin prevents frailty in this population. The tension therefore does not reflect disagreement on direction; both sources carry a null effect direction, but rather disagreement on the inferential weight appropriate to each source within the synthesis.

### Immune and Inflammation Outcomes

Two RCTs in the curated corpus directly examined metformin effects on immune and inflammatory biomarkers, with heterogeneous participant populations spanning type 2 diabetes with obesity and frail older adults with sarcopenia. Schiapaccassa 2019 [bundle:33] was a 30-day head-to-head RCT comparing vildagliptin and metformin in drug-naïve women with diabetes and obesity, evaluating vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides. Effects of Metformin on Biomarkers 2026 [bundle:31] was the MET-PREVENT RCT in frail/sarcopenic older adults, examining biomarkers over a 4-month treatment window with a placebo comparator. Durations and populations thus differ markedly, with the diabetes cohort studied at 30 days and the sarcopenic cohort at approximately 4 months.

The source-traced p-values indicate that several immune and inflammatory endpoints shifted within the trials, but the directions were not uniformly negative. Schiapaccassa 2019 [bundle:33] reported a panel of immune/vascular associations with P < 0.05, P < 0.01, P < 0.001, P = 0.02, P = 0.03, P = 0.008, P = 0.05, P = 0.0005, and P = 0.01, alongside null contrasts at P = 0.49, P = 0.55, P = 0.21, and P = 0.10. Effects of Metformin on Biomarkers 2026 [bundle:31] reported a single scripted biomarker result of P = 0.04 in frail/sarcopenic older adults, alongside the insulin reduction of −178 pg/mL (median change between baseline and 4 months). The numeric distribution therefore supports short-window vascular/inflammatory modulation in metformin-controlled diabetes, with a more contained signal in frail older adults.

Mechanistically, the immune findings map onto established metformin pathways, including AMPK activation, partial inhibition of mitochondrial complex I, and downstream effects on NF-κB signaling and cytokine output. In the clinical RCT setting represented by Schiapaccassa 2019 [bundle:33], both metformin and vildagliptin are recognized to have vasculoprotective properties, providing a mechanistic substrate for the inflammatory and oxidative-stress signal reductions observed within the 30-day window. The mechanistic substrate underlying this functional finding is consistent with reduced insulin-mediated inflammation and altered incretin-axis activity, which intersect with the biomarkers measured in both human RCTs. Effects of Metformin on Biomarkers 2026 [bundle:31] extends this mechanistic account to skeletal-muscle and inflammatory endpoints in sarcopenia, where P = 0.04 supports a detectable, if modest, biomarker effect.

Within-corpus tension on the immune outcome class is mild but worth noting. However, the effect direction tagged in the corpus differs by trial: Schiapaccassa 2019 [bundle:33] is annotated as "mixed" reflecting its mixture of significant and non-significant p-values (P = 0.49, P = 0.55, P = 0.21, P = 0.10 among the nulls), whereas Effects of Metformin on Biomarkers 2026 [bundle:31] is annotated as "negative" with P = 0.04. The clinical RCT head-to-head design of Schiapaccassa 2019 [bundle:33] versus the placebo-controlled sarcopenia design of Effects of Metformin on Biomarkers 2026 [bundle:31] likely contributes to this directional discrepancy, and the curated corpus does not adjudicate which window or population dominates the overall inflammation signal. Readers should therefore interpret the negative direction as the modal, but not unanimous, immune outcome across the two direct RCTs.

### Longevity Outcomes

Two observational cohorts constitute the longevity evidence available in the corpus, and both are positioned as indirect evidence relative to a canonical trial endpoint. In Orchard 2021 [bundle:30], the source dataset comprised older adults followed for cancer incidence and mortality, with metformin exposure captured as a longitudinal covariate alongside aspirin use. The study design was observational rather than randomized, which limits causal inference but permits exploration of effect modification by glycemic control status. Metformin exposure was modeled as a time-varying binary variable, and the mortality endpoint combined cancer-specific and all-cause deaths depending on the sub-analysis.

Quantitative findings within Orchard 2021 [bundle:30] were strongly stratified by diabetes control. Among participants with controlled diabetes, metformin users showed a significant reduction in cancer mortality compared with nonusers, with an adjusted hazard ratio of 0.24 and a 95% confidence interval of 0.07 to 0.80. The wide confidence interval, anchored at 0.07, signals substantial uncertainty around the magnitude of the controlled-diabetes effect despite its statistical significance.

 In the full cohort, metformin exposure was not associated with mortality during the first three [months of follow-up], indicating a null early-window effect. The mechanistic substrate underlying this null finding likely reflects both the aggressive biology of glioblastoma and the limited time for any metabolic intervention to remodel tumor microenvironment during the immediate post-diagnostic period.

Within-corpus tensions arise when Orchard 2021 [bundle:30] and Maio 2026 [bundle:19] are read together: Orchard 2021 [bundle:30] reports a strong protective association in a controlled-diabetes subgroup, whereas Maio 2026 [bundle:19] reports no association in a full glioblastoma cohort. These two findings are not strictly contradictory because the populations, follow-up windows, and endpoint definitions differ, but they illustrate that metformin’s longevity signal is highly context-dependent. The directionality in Orchard 2021 [bundle:30]’s controlled subgroup is protective, while the effect direction in Maio 2026 [bundle:19]’s full cohort is unclear, underscoring that boundary conditions such as glycemic control and tumor biology remain to be established.

### Safety and Comorbidity Outcomes

The single safety-relevant source in the present corpus is Abed 2024 [bundle:18], a randomized clinical trial evaluating metformin phonophoresis combined with exercise therapy in adults with chronic knee osteoarthritis. The study randomized patients into comparator arms and tracked pain, range of motion, and physical function as co-registered safety and functional endpoints, with multiple between-arm contrasts reported across the trial's measurement battery. source-level metadata indicates sixteen distinct p-value contrasts for this trial, spanning both mechanistic biomarker endpoints and clinical functional scales. Sample size and follow-up duration are not specified in the available source excerpt, so the trial's quantitative power must be interpreted qualitatively rather than from a registry-derived n.

 One contrast reached P = 0.994, indicating essentially null between-arm separation on that specific endpoint. The mix of strongly significant, marginally significant, and clearly null contrasts is consistent with a multi-domain endpoint battery rather than a uniform drug effect across all measured variables. Per the within-source reporting convention, no effect sizes, confidence intervals, or absolute event counts are available, so the evidence synthesis should be consulted for the study × endpoint p-value matrix rather than for pooled estimates.

Mechanistically, Abed 2024 [bundle:18] sits at the intersection of pharmacologic exposure (metformin delivered via phonophoresis, a transdermal ultrasound-mediated route) and an exercise-based comparator, with endpoints spanning symptomatic pain, joint range of motion, and global physical function. The convergence of strongly significant p-values on certain contrasts (notably the P = 0.001 and P = 0.002 readings) alongside clearly null contrasts (P = 0.994, P = 0.503) is interpretable as a domain-specific rather than systemic metformin effect, plausibly mediated by local anti-inflammatory or chondroprotective substrates rather than the systemic AMPK-related pathways more commonly invoked in oral metformin literature. As a clinical RCT, the study contributes direct human evidence; however, the phonophoresis route limits mechanistic transferability to standard oral metformin regimens used in cardiometabolic and aging trials.

Within the corpus, the safety comorbidity outcome class is anchored by a single source (Abed 2024 [bundle:18]), so within-corpus tensions cannot be enumerated across multiple studies at this resolution. The trial's internal tension — significant benefit on selected endpoints coexisting with null findings on others — can be interpreted as endpoint heterogeneity rather than as inter-study disagreement, given that no second safety comorbidity source is available to triangulate. The source's effect direction is recorded as unclear, which reinforces the interpretation that aggregate safety conclusions for metformin in this outcome class cannot be drawn from the present corpus alone and that additional clinical RCT evidence is needed before firm recommendations can be issued.

## Cross-Domain Synthesis

The most consequential tension in this corpus lies between the surrogate-endpoint optimism that dominates direct clinical RCTs of metformin in cardiometabolic disease and the null or unclear findings that dominate direct RCTs on functional, frailty, and hard-outcome endpoints. The mechanism-level resolution is straightforward: metformin reliably lowers glucose in patients with dysregulated glycemia (the canonical ADA 2024 HbA1c target being 7% for most adults with diabetes), but HbA1c is a surrogate endpoint (Ioannidis 2005) whose translation into preserved muscle function, gait speed, or hard aging endpoints is not guaranteed. The boundary condition is population-dependent — the surrogate effect transfers when the cohort's morbidity is driven by hyperglycemia (Park 2024 [bundle:2], Mohan 2026 [bundle:5], Sahay 2026 [bundle:4]), and fails to transfer when the morbidity driver is aging-related sarcopenia or functional decline (Tavabi 2021 [bundle:26], Espinoza 2025a [bundle:28]). What would resolve the tension is a metformin RCT with a pre-specified hierarchical endpoint strategy that includes both a glycemic surrogate and a functional/hard outcome in the same population at adequate power.

Another cross-domain tension concerns the divergence between mechanistic/biomarker evidence that metformin shifts aging-relevant biology and the absence of consistent, direct human-RCT confirmation on the corresponding functional outcome. At the same time, the direct immune-biomarker RCT of Effects of Metformin on Biomarkers 2026 [bundle:31] in frail/sarcopenic older adults found metformin reduced circulating insulin (median change between baseline and 4 months: -178 pg/ml, P = 0.04), which is the mechanistic opposite of what one might want if muscle anabolism were the goal. The mechanism-vs-clinical gap runs in a particular direction: metformin moves proximal molecular readouts in the expected direction, but distal functional outcomes fail to follow. The boundary condition appears to be dose, duration, and baseline phenotype — Marcelo-Calvo 2026 [bundle:12] enrolled non-diabetic HIV-positive participants on stable antiretrovirals, a population where the driver of accelerated aging is viral reservoir and inflammation rather than glycemia. Evidence that would resolve the tension would require a direct RCT pairing mechanistic/biomarker endpoints with co-primary functional endpoints (for example, handgrip strength, with EWGSOP2 sarcopenia cutoffs of 27 kg for men and 16 kg for women, Cruz-Jentoft 2019) in the same cohort, powered to detect both.

Another tension sits inside the cardiometabolic class itself and merits adjudication as a cross-domain disagreement because the RCT evidence on body mass index is itself contradictory across populations. Hu 2021 [bundle:9] (a behavioral weight-loss RCT with metformin up to 2000 mg/day, ADA 2024 ceiling dose) reports positive BMI effects (P = 0.002 among the reported p-cluster spanning the urate and weight endpoints), whereas Han 2020 [bundle:7] (24-week RCT of ipragliflozin added to metformin+pioglitazone in T2D with comorbid NAFLD), Qin 2025 [bundle:3] (sitagliptin/gliclazide added to metformin, treatment-naive T2D), and Comparison of Efficacy and Safety 2022 [bundle:32] (vildagliptin 50 mg BID vs 100 mg SR on top of metformin) report null BMI effects. The mechanism-level explanation is that metformin-induced weight loss tends is visible when metformin delivered as monotherapy with structured lifestyle co-intervention (Hu 2021 [bundle:9]), but is attenuated or absent when metformin is the background therapy and the randomized contrast is between add-on agents whose own metabolic effects compete (Han 2020 [bundle:7], Qin 2025 [bundle:3]). The boundary condition therefore is comparator and design — metformin-vs-placebo designs preserve the weight signal (Hu 2021 [bundle:9]), while add-on-to-metformin designs dilute it. The practical implication is that null BMI in add-on trials (Han 2020 [bundle:7], Qin 2025 [bundle:3], Kim 2024 [bundle:10]) should not be cited as evidence that metformin lacks a weight effect; the relevant comparison class is monotherapy RCTs. Evidence that would adjudicate the conflict would be a direct head-to-head factorial trial pairing metformin monotherapy versus placebo with and without structured lifestyle support, measuring BMI as a pre-specified endpoint stratified by baseline BMI above the WHO 2000 overweight threshold of 25 kg/m2 versus obesity threshold of 30 kg/m2.

Another tension — and the one with the largest severity score in the cross-study disagreement map — is the explicit null-vs-positive and null-vs-negative conflict on HbA1c across direct RCTs that should, in principle, be measuring the same thing. Han 2020 [bundle:7] reports null HbA1c effect (direct RCT) because the randomized contrast is ipragliflozin add-on versus metformin+pioglitazone background. The mechanism-level explanation is straightforward once the design is unpacked: Mohan 2026 [bundle:5] randomized to add or omit the glimepiride+voglibose intensification, so metformin+background loses; Sahay 2026 [bundle:4] randomized between two glimepiride-containing regimens that both already include metformin, so the metformin contrast is washed out; Han 2020 [bundle:7] randomized the SGLT2 add-on, with metformin shared by both arms. The boundary condition is therefore the comparator: when the randomized contrast isolates metformin as the agent under test (Mohan 2026 [bundle:5]), HbA1c effects are large and statistically robust; when metformin is the shared background (Sahay 2026 [bundle:4], Han 2020 [bundle:7], Park 2024 [bundle:2], Qin 2025 [bundle:3], Kim 2024 [bundle:10], Comparison of Efficacy and Safety 2022 [bundle:32]), HbA1c effects of metformin cannot be estimated and appear null by construction. This resolves much of the apparent cardiometabolic heterogeneity — it is not that metformin fails; it is that most direct RCTs in the corpus do not actually randomize metformin against a true control.

Finally, the immune-class findings warrant a cross-domain reading because they show that even within a single mechanistic axis — inflammation and vascular function — metformin can move a surrogate in the expected direction while leaving a co-measured downstream biomarker unchanged. Schiapaccassa 2019 [bundle:33] (direct RCT in drug-naïve women with T2D and obesity, 30 days, head-to-head metformin vs vildagliptin) reports mixed effects across a battery of immune and vascular endpoints with multiple p-values ranging from P < 0.001 through P = 0.55, indicating selective immune modulation rather than uniform anti-inflammatory action. Effects of Metformin on Biomarkers 2026 [bundle:31] (direct RCT in frail/sarcopenic older adults) reports a negative effect on insulin (P = 0.04) — metformin reduces insulin — but the broader biomarker panel is not reported as uniformly improved. The mechanism-vs-clinical gap here is at the surrogate-vs-functional level: metformin may shift an inflammatory readout (Schiapaccassa 2019 [bundle:33]) without producing the corresponding functional translation, and conversely may shift insulin downward (Effects of Metformin on Biomarkers 2026 [bundle:31]) in a population where reduced anabolic signaling is itself undesirable. The boundary condition is baseline inflammatory and anabolic state; in obese hyperglycemic patients, insulin reduction is beneficial, while in sarcopenic older adults it may be harmful. Evidence that would resolve this would be a direct RCT stratifying inflammatory and anabolic biomarkers at baseline and prespecifying direction-of-effect heterogeneity, rather than reporting overall main effects that wash the population-specific signals into null or mixed averages. The Auditable bottom line of this synthesis is that metformin's evidence base is genuinely context-dependent: when glycemia is the driver and metformin is the randomized contrast, effects are reliable; when metformin is the background and aging biology is the outcome, effects are null or mixed; and when observational longevity signals are read off diabetic cohorts, they cannot be transported to non-diabetic older adults without a direct RCT that the current corpus does not supply.

## Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 33 curated reference papers, the evidence base for Metformin shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic, immune. Null findings dominate: contextual other, frailty. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Metformin broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 33 included sources. The evidence-tier distribution is: B2 (n=18), A1 (n=15). By directness, the breakdown is: indirect (n=18), direct (n=15). 25 of 33 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: adults; type 2 diabetes patients; frail / sarcopenic adults; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Several canonical trial types and evidence streams are absent from the curated corpus, which constrains the breadth of the headline conclusions. Absence of a dedicated hard-outcome RCT means any claim that metformin alters mortality, major adverse cardiovascular events, or incident frailty in non-diabetic aging adults is not supported by the corpus as constituted.

A substantial fraction of the corpus rests on single-source observations that cannot be internally replicated. Single-trial outcomes cannot be cross-checked against an independent source within this corpus, so any pooled or summary inference drawn from them is statistically underpowered; the Mueller 2021 [bundle:8] short-chain-fatty-acid findings (n = 121 overweight/obese adults previously treated for solid tumors) and the Schiapaccassa 2019 [bundle:33] 30-day vascular-function results in drug-naïve women with diabetes and obesity face the same constraint. Conclusions drawn from these one-off endpoints should be treated as hypothesis-generating rather than confirmatory.

The enrolled populations cluster heavily around type 2 diabetes, with non-diabetic and special-population evidence appearing only in narrow pockets. Non-diabetic cohorts are limited to Marcelo-Calvo 2026 [bundle:12] (older people with HIV), Abed 2024 [bundle:18] (chronic knee osteoarthritis), Behbudi 2025 [bundle:21] (70 non-diabetic ischemic-stroke patients), and the exercise-training studies in adults at risk for metabolic syndrome (Malin 2026a [bundle:6]; Malin 2026b [bundle:11]). External validity to healthy agers, women across the reproductive lifespan, and racially/ethnically diverse populations outside India and China is therefore unsupported.

Several clinically relevant endpoints are simply not measured in the available sources. Body-mass-index findings are internally inconsistent across the corpus: Hu 2021 [bundle:9] reports a positive metformin effect on BMI, whereas Mohan 2026 [bundle:5], Kim 2024 [bundle:10], Sahay 2026 [bundle:4], Han 2020 [bundle:7], and Agarwal 2026 [bundle:16] report null effects on the same outcome, and Kumari 2026 [bundle:15] reports a negative BMI effect — a partial conflict that cannot be adjudicated from the sources in hand. Ioannidis 2005 surrogate-endpoint caution applies directly: HbA1c and BMI movement in these trials does not establish hard-outcome benefit, particularly given that the standard glycemic target for most adults with diabetes is 7% per ADA 2024.

Finally, follow-up duration and dose-exposure coverage are too short to detect late-emerging benefits or harms. The ESPINOZA-tracked gait, grip, and physical-performance trajectories are not present in any of the sources, so the clinical meaningfulness of the biomarker shifts cannot be tied to functional anchors such as the 0.8 m/s frailty threshold per Studenski 2011 or the EWGSOP2 grip cutoffs of 27 kg (men) / 16 kg (women) per Cruz-Jentoft 2019.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 33 included sources. The evidence tiers are B2 (n=18), A1 (n=15), and directness is indirect (n=18), direct (n=15). Effect directions are unclear (n=19), null (n=5), negative (n=4), positive (n=3), mixed (n=2), with 25 sources carrying source-traced p-values and 284 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 33 included sources on Metformin Intervention Metformin Treatment Effects across 6 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between Kim 2024 [bundle:10] and Hu 2021 [bundle:9] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 2 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 9 | 10 | mixed, negative, null, positive, unclear | conflict-resolution gap |
| frailty | 1 | 1 | null | replication gap |
| immune and inflammation | 2 | 0 | mixed, negative | replication gap |
| contextual adjacent evidence | 2 | 5 | null, unclear | replication gap |
| safety and comorbidity | 1 | 0 | unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: unclear |
| P2 | cardiometabolic: conflict-resolution gap | 9 direct and 10 indirect sources; direction profile: mixed, negative, null, positive, unclear |
| P3 | frailty: replication gap | 1 direct and 1 indirect sources; direction profile: null |
| P4 | immune and inflammation: replication gap | 2 direct and 0 indirect sources; direction profile: mixed, negative |
| P5 | contextual adjacent evidence: replication gap | 2 direct and 5 indirect sources; direction profile: null, unclear |

### Next-Study Design Recommendation

The next high-yield study for Metformin Intervention Metformin Treatment Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Schiapaccassa 2019 [bundle:33]; tier=A1; directness=direct; endpoint=immune; direction=mixed; representative statistic=P = 0.0005.
- Park 2024 [bundle:2]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.0001.
- Qin 2025 [bundle:3]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
- Sahay 2026 [bundle:4]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.0001.
- Mohan 2026 [bundle:5]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.0001.
- Han 2020 [bundle:7]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.001.
- Mueller 2021 [bundle:8]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.05.
- Hu 2021 [bundle:9]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
- Kim 2024 [bundle:10]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Marcelo-Calvo 2026 [bundle:12]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Schiapaccassa 2019 [bundle:33]: outcome=immune; directness=direct; tier=A1; direction=mixed; claims=229.
- Park 2024 [bundle:2]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=161.
- Qin 2025 [bundle:3]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=149.
- Sahay 2026 [bundle:4]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=144.
- Mohan 2026 [bundle:5]: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=132.
- Han 2020 [bundle:7]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=108.
- Mueller 2021 [bundle:8]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=107.
- Hu 2021 [bundle:9]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=73.
- Kim 2024 [bundle:10]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=70.
- Marcelo-Calvo 2026 [bundle:12]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=65.
- Agarwal 2026 [bundle:16]: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=51.
- Abed 2024 [bundle:18]: outcome=safety comorbidity; directness=direct; tier=A1; direction=unclear; claims=46.
- Tavabi 2021 [bundle:26]: outcome=frailty; directness=direct; tier=A1; direction=null; claims=15.
- Effects of Metformin on Biomarkers 2026 [bundle:31]: outcome=immune; directness=direct; tier=A1; direction=negative; claims=2.
- Comparison of Efficacy and Safety 2022 [bundle:32]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=1.
- Guo 2026 [bundle:1]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=170.
- Malin 2026a [bundle:6]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=124.
- Malin 2026b [bundle:11]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=69.
- Iraji 2026 [bundle:13]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=65.
- Guo 2021 [bundle:14]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=57.
- Kumari 2026 [bundle:15]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=53.
- Li 2025 [bundle:17]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=49.
- Maio 2026 [bundle:19]: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=41.
- Shadyab 2025 [bundle:20]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=34.
- Behbudi 2025 [bundle:21]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=33.
- Inzucchi 2020 [bundle:22]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=29.
- Shen 2026 [bundle:23]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=26.
- R 2026 [bundle:24]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=20.
- Bilusic 2026 [bundle:25]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=17.
- Espinoza 2022 [bundle:27]: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=13.
- Espinoza 2025a [bundle:28]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=11.
- Espinoza 2025b [bundle:29]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=11.
- Orchard 2021 [bundle:30]: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=8.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs negative: Qin 2025 [bundle:3] vs Agarwal 2026 [bundle:16]; Agarwal 2026 [bundle:16] (negative on insulin sensitivity) vs Qin 2025 [bundle:3] (null on insulin sensitivity) — partial conflict
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Malin 2026a [bundle:6]; Kumari 2026 [bundle:15] (negative on body mass index) vs Malin 2026a [bundle:6] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Guo 2026 [bundle:1]; Kumari 2026 [bundle:15] (negative on body mass index) vs Guo 2026 [bundle:1] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Guo 2021 [bundle:14]; Kumari 2026 [bundle:15] (negative on body mass index) vs Guo 2021 [bundle:14] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Mohan 2026 [bundle:5] vs Sahay 2026 [bundle:4]; Mohan 2026 [bundle:5] (negative on hba1c) vs Sahay 2026 [bundle:4] (null on hba1c) — partial conflict
- Severity 4 null vs negative: Mohan 2026 [bundle:5] vs Han 2020 [bundle:7]; Mohan 2026 [bundle:5] (negative on hba1c) vs Han 2020 [bundle:7] (null on hba1c) — partial conflict
- Severity 4 null vs positive: Kim 2024 [bundle:10] vs Hu 2021 [bundle:9]; Hu 2021 [bundle:9] (positive on body mass index) vs Kim 2024 [bundle:10] (null on body mass index) — partial conflict
- Severity 4 null vs positive: Malin 2026b [bundle:11] vs Malin 2026a [bundle:6]; Malin 2026a [bundle:6] (positive on body weight) vs Malin 2026b [bundle:11] (null on body weight) — partial conflict

## References

- **Schiapaccassa 2019.** _30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study._ Diabetology & Metabolic Syndrome, 2019. DOI: 10.1186/s13098-019-0466-2 PMID: 31462933.
- **Guo 2026.** _HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin._ JAMA Network Open, 2026. DOI: 10.1001/jamanetworkopen.2026.15622 PMID: 42234428.
- **Park 2024.** _Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial._ Diabetes & Metabolism Journal, 2024. DOI: 10.4093/dmj.2023.0259 PMID: 38650099.
- **Qin 2025.** _Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis._ Medicine, 2025. DOI: 10.1097/MD.0000000000041061 PMID: 39792745.
- **Sahay 2026.** _Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70778 PMID: 42070788.
- **Mohan 2026.** _Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study._ Journal of Diabetes, 2026. DOI: 10.1111/1753-0407.70217 PMID: 41979234.
- **Malin 2026a.** _Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70478 PMID: 41532329.
- **Han 2020.** _Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial._ Journal of Clinical Medicine, 2020. DOI: 10.3390/jcm9010259 PMID: 31963648.
- **Mueller 2021.** _Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial._ Diabetes Care, 2021. DOI: 10.2337/dc20-2257 PMID: 34006565.
- **Hu 2021.** _Effects of a Behavioral Weight Loss Intervention and Metformin Treatment on Serum Urate: Results from a Randomized Clinical Trial._ Nutrients, 2021. DOI: 10.3390/nu13082673 PMID: 34444833.
- **Kim 2024.** _A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study)._ Journal of Diabetes Research, 2024. DOI: 10.1155/2024/8915591 PMID: 38223523.
- **Malin 2026b.** _Metformin Alters Exercise Training Induced Blood Pressure and Aortic Waveform Adaptations in Adults at Risk for Metabolic Syndrome._ The Journal of Clinical Hypertension, 2026. DOI: 10.1111/jch.70215 PMID: 41796987.
- **Marcelo-Calvo 2026.** _Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial._ eClinicalMedicine, 2026. DOI: 10.1016/j.eclinm.2026.103874 PMID: 42023167.
- **Iraji 2026.** _Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in the Treatment of Melasma._ Journal of Cosmetic Dermatology, 2026. DOI: 10.1111/jocd.70983
- **Guo 2021.** _Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus._ Frontiers in Endocrinology, 2021. DOI: 10.3389/fendo.2021.712200 PMID: 34659110.
- **Kumari 2026.** _Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus._ Cureus, 2026. DOI: 10.7759/cureus.101227 PMID: 41669572.
- **Agarwal 2026.** _Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial._ Indian Journal of Endocrinology and Metabolism, 2026. DOI: 10.4103/ijem.ijem_635_25 PMID: 41918604.
- **Li 2025.** _Medication count, including statin or metformin use, is not associated with influenza vaccine responses in older adults._ Vaccine, 2025. DOI: 10.1016/j.vaccine.2025.127913 PMID: 41167013.
- **Abed 2024.** _Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee osteoarthritis: randomized clinical trial._ Journal of Orthopaedic Surgery and Research, 2024. DOI: 10.1186/s13018-024-05120-0 PMID: 39456024.
- **Maio 2026.** _Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study._ Neuro-Oncology Advances, 2026. DOI: 10.1093/noajnl/vdag041 PMID: 41788737.
- **Shadyab 2025.** _Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2025. DOI: 10.1093/gerona/glaf095 PMID: 40388602.
- **Behbudi 2025.** _Effect of Metformin on Clinical Course of Non-Diabetic Patients with Ischemic Stroke._ Galen Medical Journal, 2025. DOI: 10.31661/gmj.v14i.4049 PMID: 42038850.
- **Inzucchi 2020.** _MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D._ Journal of the Endocrine Society, 2020. DOI: 10.1210/jendso/bvaa046.414
- **Shen 2026.** _Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70598 PMID: 41755790.
- **R 2026.** _Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape._ Annals of Neurosciences, 2026. DOI: 10.1177/09727531261421807 PMID: 41930282.
- **Bilusic 2026.** _The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients._ EMBO Molecular Medicine, 2026. DOI: 10.1038/s44321-026-00408-6 PMID: 41942753.
- **Tavabi 2021.** _A Randomized Placebo-Controlled Trial of Metformin for Frailty Prevention in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.2991
- **Espinoza 2022.** _CLINICAL TRIAL OF METFORMIN FOR FRAILTY PREVENTION IN COMMUNITY-DWELLING OLDER ADULTS WITH PRE-DIABETES._ Innovation in Aging, 2022. DOI: 10.1093/geroni/igac059.2117
- **Espinoza 2025a.** _A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1648
- **Espinoza 2025b.** _METFORMIN TO TARGET FRAILTY IN OLDER ADULTS._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1104
- **Orchard 2021.** _Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.2339
- **Effects of Metformin on Biomarkers 2026.** _3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial._ Age and Ageing, 2026. DOI: 10.1093/ageing/afaf368.097
- **Comparison of Efficacy and Safety 2022.** _Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial._ National Journal of Physiology, Pharmacy and Pharmacology, 2022. DOI: 10.5455/njppp.2022.12.062851202217862022

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "732896ca-31c9-4fb7-9ef3-f8e751d670f0",
  "title": "Research Synthesis: Metformin Intervention Metformin Treatment Effects \u2014 full paper"
}